KBC Group’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

KBC Group’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-11,300	Closed	-$102K	–	1330
2021 Q3	$102K	Hold	11,300	–	–	﹤0.01%	1163
2021 Q2	$135K	Buy	11,300 +9,000	+391%	+$102K	﹤0.01%	1135
2021 Q1	$29K	Hold	2,300	–	–	﹤0.01%	1269
2020 Q4	$36K	Hold	2,300	–	–	﹤0.01%	1229
2020 Q3	$22K	Hold	2,300	–	–	﹤0.01%	1209
2020 Q2	$21K	Hold	2,300	–	–	﹤0.01%	1249
2020 Q1	$15K	Hold	2,300	–	–	﹤0.01%	1263
2019 Q4	$19K	Buy	2,300 +2,130	+1,253%	+$19.6K	﹤0.01%	1456
2019 Q3	$2K	Sell	170 -1,130	-87%	-$12.7K	﹤0.01%	1471
2019 Q2	$14K	Hold	1,300	–	–	﹤0.01%	1429
2019 Q1	$12K	Buy	1,300 +450	+53%	+$4.6K	﹤0.01%	1390
2018 Q4	$10K	Hold	850	–	–	﹤0.01%	1293
2018 Q3	$14K	Hold	850	–	–	﹤0.01%	1376
2018 Q2	$12K	Buy	850 +400	+89%	+$6.64K	﹤0.01%	1276
2018 Q1	$9K	Hold	450	–	–	﹤0.01%	1266
2017 Q4	$7K	Buy	+450	New	+$6.7K	﹤0.01%	1252

Other funds holding SGMO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

LOAMS

Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $3.14B AUM 46.44% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

KBC Group's SGMO Position: Q4 2021 in Review

KBC Group sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2021, closing a stake of 11,300 shares — an estimated $102K sold.

KBC Group first reported a position in SGMO in Q4 2017 and held it in 16 quarters. The position peaked at $135K in Q2 2021. 193 funds tracked by Wall St. Rank hold SGMO as of Q4 2021.

KBC Group reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2021 after selling out during the quarter.
KBC Group sold 11,300 SANGAMO THERAPEUTICS INC shares in Q4 2021, an estimated $102K.
KBC Group first reported a position in SANGAMO THERAPEUTICS INC in Q4 2017 and held it in 16 quarters.
KBC Group's SANGAMO THERAPEUTICS INC position peaked at $135K in Q2 2021.
193 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2021.

Based on KBC Group's 13F filing for Q4 2021, filed 3 Feb 2022.